Overview

A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety including immunogenicity and efficacy of LBEC0101 50 mg subcutaneous weekly injection when co-administered with MTX
Phase:
Phase 3
Details
Lead Sponsor:
LG Life Sciences
Treatments:
Methotrexate